Integral Launches World’s First Stablecoin-based Crypto Prime Broker

30.9.2025 10:00:00 EEST | Business Wire | Press release

Integral, a global leader in FX and digital asset technology, today announced the launch of PrimeOne, the world’s first stablecoin-based crypto prime brokerage. Built on the Codex Layer-1 EVM blockchain, PrimeOne delivers institutional-grade credit, trading, and net settlement in a single, integrated platform.

PrimeOne allows clients to trade with leading crypto market makers and exchanges through a single account - eliminating the need to maintain separate relationships across venues. Clients benefit from faster time to market, streamlined onboarding with just one AML/KYC check, and no credit requirement.

Unlike traditional models, PrimeOne’s on-chain infrastructure ensures clients retain control of their assets at all times. As open positions change in value, USD stablecoin-based margin automatically moves between counterparties’ wallets in real time, virtually eliminating counterparty credit risk. Trading limits are dynamically set based on margin balances held by PrimeOne participants.

The result is a complete trading ecosystem that offers superior liquidity, improved operational efficiency, and dramatically reduced capital requirements and credit exposure.

Launched at a pivotal time of accelerating institutional adoption, PrimeOne combines the resiliency of institutional-grade infrastructure with the innovations of decentralized finance. By leveraging stablecoins and real-time margin exchange, PrimeOne prevents defaults from cascading across participants - delivering a more resilient, democratized credit network.

Harpal Sandhu, CEO of Integral, commented: “As institutional adoption of crypto accelerates, the lack of accessible credit remains the last major hurdle to widespread participation. As the technology provider powering more than $1 trillion of FX trading monthly, Integral is now bringing our best-in-class infrastructure to digital assets. PrimeOne reduces risk, cost, and complexity while unlocking liquidity, profitability, and confidence in crypto trading.”

Scotte Moegling, from Virtu Financial, also said: “We are strong proponents of the emergence of the blockchain technology, and PrimeOne exemplifies the powerful democratizing capabilities that it delivers. PrimeOne will enable investors access to greater competitive pricing with less risk, unlocking significant growth potential for crypto trading on the platform.”

Peter Wisniewski, Managing Partner of Europa Partners, added: “PrimeOne is a gateway to the future of credit in cryptocurrency markets. The ease of setup, speed of onboarding, and access to liquidity will allow us to trade more profitably, more efficiently and at lower costs. This will help us deliver higher returns and capitalize on unprecedented opportunities in cryptocurrency markets.”

For more information about PrimeOne, visit primeone.net.

About Integral

Integral is the currency technology partner to hundreds of financial institutions, including banks, brokers, investors and cross-border payment companies, who have embedded Integral’s technology in their workflows and customer-facing services.

Adopted first by the financial markets and now integrated across all industries - our embedded FX and digital asset services are solving the challenges faced by every global organization.

Founded in 1993, we support customers from our offices in Palo Alto, New York, London, Tokyo, Singapore and Bengaluru.

Additional information is available at integral.com.

About PrimeOne

PrimeOne is a next-generation prime brokerage service for crypto markets. With a single account, clients can trade with any counterparty they choose. At its core, it is a breakthrough credit mechanism that transfers mark-to-market gains and losses in real time, ensuring safe and efficient trading between participants. This innovation makes PrimeOne the only truly scalable credit solution - enabling rapid client onboarding without balance sheet exposure.

Additional information is available at primeone.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930526634/en/

Contacts

Integral, 380 Portage Avenue, Palo Alto, California 94306
email: integral@aspectusgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom